Similar articles

• Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.

  Cowan PA, Heizer KE. Cowan PA, et al. Nephrol Nurs J. 2000 Dec;27(6):623-5. Nephrol Nurs J. 2000. PMID: 16649344 Review.
• Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.

  Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T. Uslu A, et al. Nephrology (Carlton). 2008 Feb;13(1):80-6. doi: 10.1111/j.1440-1797.2007.00866.x. Nephrology (Carlton). 2008. PMID: 18199109
• Sirolimus: new preparation. No tangible advance in renal transplantation.

  [No authors listed] [No authors listed] Prescrire Int. 2002 Dec;11(62):165-6. Prescrire Int. 2002. PMID: 12469693
• Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?

  Nashan B. Nashan B. Transplant Rev (Orlando). 2009 Jan;23(1):47-52. doi: 10.1016/j.trre.2008.08.005. Transplant Rev (Orlando). 2009. PMID: 19027616 Review.
• Calcineurin inhibitor-free immunosuppression in kidney transplantation.

  Guerra G, Srinivas TR, Meier-Kriesche HU. Guerra G, et al. Transpl Int. 2007 Oct;20(10):813-27. doi: 10.1111/j.1432-2277.2007.00528.x. Epub 2007 Jul 20. Transpl Int. 2007. PMID: 17645419 Review.